NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

What Happened?

A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. 

The retreat in oil prices provided temporary relief to a market that was volatile amid geopolitical tensions. Lower energy costs can help temper inflation, which had been a primary concern for the economy and corporate profits. As a result, major indices like the S&P 500 and Dow Jones Industrial Average saw significant gains. This positive macroeconomic development boosted investor confidence across most sectors, leading to widespread buying activity that included major stocks within the healthcare industry, which rose in tandem with the overall market.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Testing & Diagnostics Services company NeoGenomics (NASDAQ:NEO) jumped 4.3%. Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.
• Immuno-Oncology company Natera (NASDAQ:NTRA) jumped 4.6%. Is now the time to buy Natera? Access our full analysis report here, it’s free.
• Generic Pharmaceuticals company Amphastar Pharmaceuticals (NASDAQ:AMPH) jumped 6%. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it’s free.

Zooming In On Amphastar Pharmaceuticals (AMPH)

Amphastar Pharmaceuticals’s shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 10 days ago when the stock dropped 6.1% on the news that the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses. According to the Bureau of Labor Statistics, the economy lost 92,000 nonfarm payroll jobs, a stark reversal from the 50,000 gain that was anticipated by economists. The healthcare sector, typically a consistent source of job growth, shed 28,000 positions. This disappointing data has raised investor concerns about a potential economic slowdown, which could lead to reduced healthcare spending and demand for services, contributing to the sector's decline in the market.

Amphastar Pharmaceuticals is down 26.5% since the beginning of the year, and at $19.44 per share, it is trading 36.9% below its 52-week high of $30.81 from September 2025. Despite the year-to-date decline, investors who bought $1,000 worth of Amphastar Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $1,054.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.